emibetuzumab emibetuzumab emibetuzumab (inn) (ly2875358) is a humanized monoclonal antibody designed for the treatment of cancer. it is in phase ii trials for patients with nsclc emibetuzumabmonoclonal antibodytype?sourcehumanized (from mouse)targethgfrclinical dataother namesly2875358atc codenoneidentifierscas number1365287-97-3iuphar/bps7748chemspidernoneuniimo4k3gdn1ichemical and physical dataformulac6356h9810n1694o2014s48molar mass143719.12 g·mol−1 this drug was developed by eli lilly & company.